Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DEBIO 9902

Drug Profile

DEBIO 9902

Alternative Names: DEBIO 9902 SR; DEBIO-9902 SR implants; N-(5-chloro-2-hydroxy-3-methoxy-benzylidene)-huperzine A; Oral ZT 1; ZT 1 Long Acting; ZT 1 sustained-release SC implant; ZT-1; ZT-1 LA

Latest Information Update: 25 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese Academy of Sciences; Jiangsu Yangtze Pharma
  • Developer Debiopharm
  • Class Alkaloids; Antidementias; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Oct 2008 Debiopharm Group completes phase II (BRAINz) trial in Alzheimer's disease
  • 21 Oct 2008 Phase-I clinical trials in Alzheimer's disease of new tablet formulation in healthly elderly volunteers in USA (PO)
  • 06 Mar 2008 The phase II (BRAINz) trial is ongoing for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top